Breaking News Instant updates and real-time market news.

CATB

Catabasis Pharmaceuticals

$5.79

-0.37 (-6.01%)

08:05
10/04/16
10/04
08:05
10/04/16
08:05

Catabasis reaches target enrollment for Part B of MoveDMD trial

Catabasis Pharmaceuticals announced that target enrollment of 30 patients has been reached for Part B of the MoveDMD trial, a 12-week trial to assess the safety and efficacy of edasalonexent, CAT-1004, in Duchenne muscular dystrophy. Edasalonexent is an oral small molecule that the Company believes has the potential to be a disease-modifying therapy for DMD patients, regardless of their underlying dystrophin mutation. Catabasis has previously reported positive safety, tolerability, pharmacokinetics and biomarker results from Part A of the trial. Based on scheduling of the enrolled patients as of September 30, 2016, the Company expects to report top-line safety and efficacy results from this Phase 2 trial in the first half of Q1 2017. In the first portion of the MoveDMD trial (Part A), 17 ambulatory boys between ages 4 and 7 with a genetically confirmed diagnosis of DMD across a range of dystrophin mutations received edasalonexent. The boys were steroid naive or had not used steroids for at least six months prior to the trial. This portion of the trial was conducted at three sites in the U.S., and assessed the safety, tolerability and pharmacokinetics of edasalonexent in patients at three dosing levels during seven days of dosing. Sixteen of the boys who participated in the first part of the MoveDMD trial are participating in Part B. Phase 2 of the MoveDMD trial is a randomized, double-blind, placebo-controlled trial of approximately 30 boys to evaluate the safety and efficacy of edasalonexent in DMD over a 12-week period at five clinical trial sites in the U.S. at two dosing levels, 67 mg/kg/day and 100 mg/kg/day. The open-label extension was initiated in July and includes dosing with edasalonexent for 36 weeks beyond the 12-week placebo-controlled portion of the trial and will evaluate longer term safety and efficacy with the same clinical end points. PPMD and the Muscular Dystrophy Association are providing funding to support participant travel for the MoveDMD trial.

CATB Catabasis Pharmaceuticals
$5.79

-0.37 (-6.01%)

12/10/15
WEDB
12/10/15
NO CHANGE
Target $27
WEDB
Outperform
Catabasis results could lead to partnership discussions, says Wedbush
Wedbush analyst Liana Moussatos said Catabsis announced the initiation of its Phase 2a trial of CAT-2054, its orally available SREBP inhibitor, in patients with hypercholesterolemia. Moussatos believes results from this trial could provide a basis for partnering discussions with a Big Pharma company with a presence in the metabolic space. The analyst sees potential peak worldwide sales of over $5.7B, and a partnering deal could have a lucrative upfront payment as well as significant milestones and royalties. Moussatos rates Catabasis an Outperform with a $27 price target on shares.
04/08/16
SBSH
04/08/16
NO CHANGE
SBSH
Citi lays out potential targets after break of Pfizer, Allergan deal
Citi analysts Yigal Nochomovitz, Liav Abraham and Joel Beatty argue that the break of the Pfizer (PFE), Allergan (AGN) merger could accelerate smaller scale acquisitions in the Biotechnology sector. The implication that larger companies could accelerate M&A activity to bolster pipelines in lieu of the mega-merger pathway aided shares in the sector this week, the analysts contend in a research note. They now believe that Ardelyx (ARDX), Medivation (MDVN), Ophthotech (OPHT), Puma Biotechnology (PBYI), Portola Pharmaceuticals (PTLA), Ultragenyx (RARE), Relypsa (RLYP) and Versartis (VSAR) have a greater probability of being acquired in the next 12-18 months. Beside these favored names for a takeover, analyst Joel Beatty sees a greater chance of Catabasis Pharmaceuticals (CATB), Intercept Pharmaceuticals (ICPT), Novavax (NVAX) and Raptor Pharmaceuticals (RPTP) getting acquired over the next 18 months.
06/08/16
COWN
06/08/16
NO CHANGE
Target $30
COWN
Outperform
Catabasis Pharmaceuticals DMD drug potential undervalued, says Cowen
Cowen noted Catabasis Pharmaceuticals halted its Phase-2 trial for CAT-2054 as it did not meet its primary endpoint in reducing LDL in hypercholesterolemia. Cowen, however, feels the shares are undervalued based on the potential of its edasalonexent drug candidate for Duchenne muscular dystropy, or DMD. The firm said the drug has the potential to be effective in all DMD patients regardless of the patient's underlying dystrophin mutation. Cowen maintained its Outperform rating and $30 price target on Catabasis shares.
06/09/16
SBSH
06/09/16
NO CHANGE
Target $8
SBSH
Buy
Catabasis Pharmaceuticals price target lowered to $8 from $16 at Citi
Citi analyst Joel Beatty halved his price target for Catabasis Pharmaceuticals to $8 and removed CAT-2054 from his model after the agent failed to lower cholesterol on top of statins in a Phase 2 trial. The analyst, however, continues to see favorable risk/reward into Phase 2 data in late 2016 for lead agent CAT-1004 in Duchenne Muscular Dystrophy. Beatty keeps a Buy rating on Catabasis.

TODAY'S FREE FLY STORIES

VMI

Valmont

$169.70

-1.4 (-0.82%)

07:24
01/23/18
01/23
07:24
01/23/18
07:24
Downgrade
Valmont rating change  »

Valmont downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LITE

Lumentum

$45.20

-3.65 (-7.47%)

07:22
01/23/18
01/23
07:22
01/23/18
07:22
Upgrade
Lumentum rating change  »

Lumentum upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Feb

MAC

Macerich

$66.00

2.25 (3.53%)

07:22
01/23/18
01/23
07:22
01/23/18
07:22
Periodicals
Ontario Teachers' in talks with investors on Macerich bid, Bloomberg reports »

Ontario Teachers'…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Feb

07:22
01/23/18
01/23
07:22
01/23/18
07:22
Conference/Events
Washington Journal holds discussion on resolving government shutdown »

The Washington…

NFLX

Netflix

$227.58

7.12 (3.23%)

07:21
01/23/18
01/23
07:21
01/23/18
07:21
Recommendations
Netflix analyst commentary  »

Netflix price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jan

HSGX

Histogenics

07:21
01/23/18
01/23
07:21
01/23/18
07:21
Syndicate
Breaking Syndicate news story on Histogenics »

Histogenics 2.34M share…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

GAIA

Gaia

$11.90

-0.05 (-0.42%)

07:21
01/23/18
01/23
07:21
01/23/18
07:21
Conference/Events
Gaia management to meet with B. Riley »

Meeting to be held in Los…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Jan

07:20
01/23/18
01/23
07:20
01/23/18
07:20
General news
Treasury Market Outlook: global yields tracked lower overnight »

Treasury Market Outlook:…

07:18
01/23/18
01/23
07:18
01/23/18
07:18
Conference/Events
Federal Reserve Bank of Chicago President participates in a discussion »

Chicago Federal Reserve…

STT

State Street

$108.99

1.38 (1.28%)

07:17
01/23/18
01/23
07:17
01/23/18
07:17
Hot Stocks
State Street sees Beacon savings realized 18 months ahead of plan by mid-2019 »

In slides ahead of its Q4…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

07:17
01/23/18
01/23
07:17
01/23/18
07:17
Conference/Events
The Chicago Council on Global Affairs to hold a panel discussion »

The Chicago Council on…

W

Wayfair

$90.64

2.8 (3.19%)

07:17
01/23/18
01/23
07:17
01/23/18
07:17
Downgrade
Wayfair rating change  »

Wayfair downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

07:16
01/23/18
01/23
07:16
01/23/18
07:16
Conference/Events
CFA Society of Columbus to hold a dinner meeting »

Ian Wallace of Third…

VYGR

Voyager Therapeutics

$20.23

1.56 (8.36%)

07:13
01/23/18
01/23
07:13
01/23/18
07:13
Hot Stocks
Voyager Therapeutics announces FDA clearance of VY-AADC IND application »

Voyager Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TBK

Triumph Bancorp

$37.00

1 (2.78%)

07:13
01/23/18
01/23
07:13
01/23/18
07:13
Upgrade
Triumph Bancorp rating change  »

Triumph Bancorp upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jan

07:13
01/23/18
01/23
07:13
01/23/18
07:13
Conference/Events
Boston University to release survey »

Boston University…

CAT

Caterpillar

$170.89

0.48 (0.28%)

07:12
01/23/18
01/23
07:12
01/23/18
07:12
Upgrade
Caterpillar rating change  »

Caterpillar upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jan

GPRO

GoPro

$6.30

0.01 (0.16%)

07:12
01/23/18
01/23
07:12
01/23/18
07:12
Downgrade
GoPro rating change  »

GoPro downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Feb

VZ

Verizon

$53.46

1.55 (2.99%)

07:11
01/23/18
01/23
07:11
01/23/18
07:11
Periodicals
Verizon mulls sports gambling as legalization nears, Bloomberg reports »

Verizon is mulling…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 25

    Jan

SRNE

Sorrento Therapeutics

$7.75

1.35 (21.09%)

, JUNO

Juno Therapeutics

$86.00

18.19 (26.83%)

07:10
01/23/18
01/23
07:10
01/23/18
07:10
Recommendations
Sorrento Therapeutics, Juno Therapeutics, Celgene analyst commentary  »

Juno acquisition bodes…

SRNE

Sorrento Therapeutics

$7.75

1.35 (21.09%)

JUNO

Juno Therapeutics

$86.00

18.19 (26.83%)

CELG

Celgene

$102.91

0.26 (0.25%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jan

  • 25

    Jan

  • 29

    Jan

  • 16

    Feb

  • 28

    Feb

  • 25

    Mar

SPX

S&P 500

07:10
01/23/18
01/23
07:10
01/23/18
07:10
Technical Analysis
S&P 500: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ENLC

EnLink Midstream

$19.25

0.5 (2.67%)

, ENLK

EnLink Midstream Partners

$18.08

0.63 (3.61%)

07:10
01/23/18
01/23
07:10
01/23/18
07:10
Conference/Events
U.S. Capital Advisors to hold a conference »

Midstream Corporate…

ENLC

EnLink Midstream

$19.25

0.5 (2.67%)

ENLK

EnLink Midstream Partners

$18.08

0.63 (3.61%)

TRGP

Targa Resources

$51.00

0.27 (0.53%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 26

    Feb

ACBFF

Aurora Cannabis

$11.65

0.8799 (8.17%)

07:10
01/23/18
01/23
07:10
01/23/18
07:10
Hot Stocks
Aurora Cannabis, CanniMed extending standstill agreement »

CanniMed Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GDX

Market Vector Gold Miners

$23.71

0.06 (0.25%)

07:09
01/23/18
01/23
07:09
01/23/18
07:09
Technical Analysis
Market Vector Gold Miners: Pivot points, pivot high broken »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VZ

Verizon

$53.46

1.55 (2.99%)

07:09
01/23/18
01/23
07:09
01/23/18
07:09
Hot Stocks
Breaking Hot Stocks news story on Verizon »

Verizon up marginally…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 25

    Jan

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.